Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1–2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.

中文翻译：

---

以血液嗜酸性粒细胞和呼出气一氧化氮为中心的哮喘发作风险量表原型的推导

降低哮喘发作的风险是当前哮喘管理的主要目标。我们建议根据血液嗜酸性粒细胞计数和呼出气一氧化氮 (FeNO) 推导出预测哮喘发作的风险量表。从 Novel START、CAPTAIN、QUEST、Benralizumab Phase 2b、PATHWAY、STRATOS 1-2 和 DREAM 试验（n=3051）的控制组中提取并汇总了生物标志物分层试验级别的攻击率。这些用于得出不同患者组的比率和预测的哮喘发作率。由此产生的原型风险量表显示出预测哮喘发作的潜力，这可以通过抗炎治疗来预防。